Thrombotic microangiopathy (TMA) usually occurs during the first weeks following transplantation in the setting of systemic infections or graft-versus-host reaction. However, some cases without any evidence of other complications or after autologous transplantation have been reported. Transplant-associated TMA (BMT-TMA) incidence ranges from 0% to 74%, possibly due to different diagnostic criteria. The GITMO Group provided the opportunity to retrospectively study 4334 consecutive Italian patients who received bone marrow transplants (1759 allogeneic and 2575 autologous BMT), during the 1985-1995 period. The present report focuses on patients with severe TMA requiring specific treatment. We identified nine cases of TMA as a complication of allogeneic BMT (0.51%), whereas three patients developed the syndrome after ABMT (0.13%); four of the 12 patients were not receiving CsA at the time of TMA onset. Finally, it is noteworthy that TMA occurred in seven patients as a late complication (up to 90 days after BMT). Despite intensive treatment, five of the seven patients with thrombotic thrombocytopenic purpura died. One death was observed among the five cases with hemolytic uremic syndrome.
Summary:
Thrombotic microangiopathy (TMA) usually occurs during the first weeks following transplantation in the setting of systemic infections or graft-versus-host reaction. However, some cases without any evidence of other complications or after autologous transplantation have been reported. Transplant-associated TMA (BMT-TMA) incidence ranges from 0% to 74%, possibly due to different diagnostic criteria. The GITMO Group provided the opportunity to retrospectively study 4334 consecutive Italian patients who received bone marrow transplants (1759 allogeneic and 2575 autologous BMT), during the 1985-1995 period. The present report focuses on patients with severe TMA requiring specific treatment. We identified nine cases of TMA as a complication of allogeneic BMT (0.51%), whereas three patients developed the syndrome after ABMT (0.13%); four of the 12 patients were not receiving CsA at the time of TMA onset. Finally, it is noteworthy that TMA occurred in seven patients as a late complication (up to 90 days after BMT). Despite intensive treatment, five of the seven patients with thrombotic thrombocytopenic purpura died. One death was observed among the five cases with hemolytic uremic syndrome. Keywords: bone marrow transplantation; complication; hemolytic uremic syndrome; thrombotic thrombocytopenic purpura Primary thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are well-known heterogeneous disorders best classified as thrombotic microangiopathy (TMA). TMA has now been documented as a complication of bone marrow transplantation (BMT) occurring within 5-6 months after BMT in a setting of other compli- cations. In BMT recipients a relationship has been suggested with cytomegalovirus (CMV) or fungal infection, graft-versus-host disease (GVHD) and cyclosporin A (CsA) toxicity. [1] [2] [3] [4] [5] However, some cases have been reported without any evidence of other complications or after autologous grafting (ABMT). 6, 7 Moreover, the pretransplant conditioning regimen may play a role in the pathogenesis of TMA. 8, 9 Because the occurrence of anemia, thrombocytopenia, renal impairment, fever and even of microangiopathic changes may have various causes during BMT, the diagnosis of transplant-associated TMA (BMT-TMA) requires a high degree of clinical suspicion and may be difficult to establish. Furthermore, BMT-TMA may have a wide spectrum of manifestations ranging from subclinical red cell fragmentation to fulminant microangiopathy. Consequently, the reported incidence of BMT-TMA varies highly, ranging from 0% to 74%. 4 The major cause for the above mentioned controversial results may be related to the different criteria used for the diagnosis. 2, 3, [10] [11] [12] However, there are no large studies concerning the frequency of BMT-TMA to date and published reports have mainly focused on particular subgroups at higher risk. 3, 4, 8, 9, 12 In the framework of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) we retrospectively reviewed the outcome of 4334 consecutive patients to assess BMT-TMA incidence. Since our major interest was life-threatening complications, attention was focused only on the cases with severe TMA that required specific treatment.
Patients and methods
This retrospective analysis was based on data collected by questionnaire containing information on total numbers of transplants performed and the occurrence of severe TMA during the 1985-1995 period. Questions concerning transplant procedures, patient characteristics, TMA, its treatment and outcome were included in the questionnaire. Overall, 14 cases with suspected TMA were recorded, but only 12 patients who received TMA-specific therapy were considered in this analysis.
The minimum criteria for TMA included: (1) simultaneous occurrence of at least two of the following parameters: microangiopathic hemolysis, thrombocytopenia, renal dysfunction, neurologic dysfunction, fever; (2) microangiopathic changes on blood smear with increased serum LDH activity. Clinical parameters associated with TMA were defined as the following: microangiopathic hemolysis as intravascular hemolysis with a negative Coombs test; thrombocytopenia as a platelet count Ͻ150 × 10 9 /l; TMA-related fever as an unexplained oral temperature of greater than 38°C; neurologic dysfunction defined as any abnormality observed during at least one neuropsychiatric examination. Renal dysfunction was diagnosed when either serum creatinine was Ͼ1.5 mg/dl or when its previously established elevated baseline value increased by 50%.
TTP was defined as TMA with neurologic dysfunction out of proportion to renal impairment, or with the absence of both neurologic and renal dysfunction. HUS was defined as TMA with significant renal impairment and little or no neurologic dysfunction. 13 The relevant clinical features and transplant procedures are described in Table 1 .
Results
Fourteen cases of TMA were recorded out of 4334 patients undergoing bone marrow transplantation in 25 centers during the study period. Two patients were excluded from the analysis: a thrombocytopenic boy who suffered from Pseudomonas aeruginosa septicemia and who was cured with antibiotics alone, and a girl with hematological changes indicating disseminated intravascular coagulation, who died of GVHD grade IV. Therefore, of the 1759 patients who underwent BMT for hematological disorders, nine developed severe TMA syndrome. Six had TTP and three had HUS. Three of the 2575 patients who received an autologous graft were treated for TMA (one TTP, two HUS) ( Table 1 ). The overall incidence of TMA after transplant was 0.28% and it was higher in allograft (0.51%) than in autograft recipients (0.28%) ( Table 2) .
Clinical data
There was a wide variation in age at diagnosis (3-46 years) with seven pediatric cases. Although both sexes were affected, eight out of 12 patients were female. Four patients received mismatched or unrelated grafts. BMT patients received CY as part of the conditioning regimen and nine patients were conditioned with regimens including total body irradiation (TBI) or thoracoabdominal irradiation (TAI). Hemolytic anemia (Ͻ11 g/dl) (11/12) and thrombocytopenia (12/12) with a simultaneous rise of LDH activity (Ͼ250 U/l) (12/12) were the most frequent signs of the disease at the time of diagnosis. Six of 12 patients had neurological symptoms. All patients with HUS and four of seven patients with TTP had renal involvement. Fever was present in three cases (Table 3 ), but one patient had concomitant pneumonia. Eight patients were receiving CsA either for the prophylaxis 6 or for active GVHD, 2 at the time of developing TMA. Two patients had a concomitant bacterial infection. Hepatic veno-occlusive disease (VOD) was documented in a boy with non-Hodgkin lymphoma. The median time interval from graft infusion to TMA was 91 days (range 14-240 days). Of note, seven cases had late onset TMA (Ͼ3 months after BMT) ( Table 4) .
Treatment and outcome of TMA
Therapeutic approach varied and was in agreement with the treatment policies adopted in different institutions. Out of the 12 patients, six were treated with plasma exchange. Vincristine was added as salvage treatment in two of these patients. One patient also received cyclophosphamide (case No. 1) and one high-dose intravenous immunoglobulin (case No. 12). Fresh frozen plasma was infused in four patients. Plasma exchange and infusion were not used in the remaining two children since they partially recovered with other agents (dypiridamole, high-dose corticosteroid).
Independent of the type of treatment, four patients recovered, while six (50.0%) failed to respond and died. Two patients are alive with mild symptoms of the disease. Whereas only one out of the five (20%) patients with HUS died because of both TMA and refractory underlying disease, five out of the seven (71.4%) patients with TTP died from TMA progression. Considering patient age, only 2/7 children died. In addition, five of six (83.3%) patients with Table 2 Incidence of thrombotic microangiopathies after bone marrow transplantation neurological abnormalities died from TMA. It is noteworthy that early occurrence of TMA in the post-BMT period was associated with refractory disease in four of five (80%) patients, whereas only two of the seven (28.6%) patients with late TMA onset died. Data dealing with therapy and patient outcome are summarized in Table 5 . 
Discussion
Signs of TMA are frequently observed soon after bone marrow transplantation, with a wide variability in terms of laboratory abnormalities and clinical symptoms, but the classical syndrome is a rare event. 5, 9 The exact incidence of TMA remains uncertain since there is a considerable range involving 0% to 74% of patients who undergo BMT.
Because reported cases vary widely in their clinical features, severity and response to treatment, it is crucial to distinguish the frequent subclinical cases, displaying red cell fragmentation without organ involvement, from the severe form of HUS or TTP. This distinction is of clinical relevance, since the former cases often resolve spontaneously, whereas the latter usually have a high incidence of mortality.
The purpose of our study was to investigate the incidence and outcome of BMT-related HUS/TTP requiring specific treatment. Only 12 out of 4334 patients suffered these complications. Of particular interest, seven of them were children. The clinical and laboratory features were typical of the TMA syndrome. In particular, clear evidence of microangiopathy on blood films with hemolytic anemia and thrombocytopenia was observed in almost all cases, while renal impairment and neurological disturbances were diagnosed in eight and six cases, respectively.
Although several factors may contribute to the onset of BMT-TMA, the underlying pathophysiology consists mainly of microvascular endothelial damage and abnormalities of the coagulation system. 11, 12 In our series, the high number of TMAs observed after mismatched or unrelated BMT confirms that the immunologic reaction due to genetic disparity and subsequent release of cytokines 11, 12 together with drug toxicity from agents such as CyA, 2,4 may be major triggers of microangiopathic damage. Similarly, the high number of patients receiving TBI or TAI, as part of their conditioning regimen, suggests that irradiation toxicity may contribute to the development of generalized microangiopathic syndromes following BMT. 6, 8 It is difficult to distinguish among microangiopathic disorders, since symptoms of the various syndromes may overlap. Nevertheless, on the basis of differences in clinical features and prognosis, Pettitt and Clark 2 classified BMT-TMA into four subgroups: multifactorial fulminant TMA, conditioning-associated hemolytic-uremic syndrome, CsAassociated nephrotoxicity with microangiopathic hemolytic anemia (MAHA) and CsA-associated neurotoxicity with MAHA. Most of our TTP cases can be classified as having multifactorial TMA on the basis of their clinical course which was often aggressive and rapidly fatal. In fact, five patients with TTP died irrespective of therapeutic measures, while of the two patients who survived one still has mild consumptive thrombocytopenia. Therefore, in keeping with previous reports, 2,4,9,10,14 our study confirms the limited efficacy of conventional treatments in the management of TTP syndrome following BMT. These clinical results are in contrast with those seen in primary TTP, where a high response rate may be achieved after early and intensive treatment with plasma infusion or plasmapheresis. 15 Given the minimal systemic involvement, our HUS cases fit into the conditioning-associated hemolytic-uremic syndrome group. 2 Four of these patients responded to treatment with improvement of laboratory and clinical parameters, whereas the other patient died of complications of both HUS and refractory NHL. Although our series, as well as that of other investigators, is too small to provide conclusive prognostic information, it is suggested that HUS following BMT 2, 14, 16 has a low mortality, as has been established in primary cases, 13, 17 when adequately treated during the early phase of disease. However, this favorable outcome for HUS patients is in contrast with the high mortality reported in previously published series of children and adults following BMT 9,18 but in these studies most patients were diagnosed in the setting of both severe infectionsactive CMV infection, bronchopneumonia -and GVHD. Therefore, poor results could be attributable to the above mentioned complications rather than to HUS.
Finally, we found a clear association between early occurrence of TMA and its refractoriness, whereas patients with late onset TMA rarely died. These results may be explained by the multifactorial pathophysiology of early TMA, 2 which may be associated with more cytokine release and therefore more endothelial damage.
In conclusion, a wide range in incidence of TMA has been reported after both autologous and allogeneic BMT, likely due to different diagnostic criteria. Although our retrospective study may have several limitations which might have led to an underestimation of the overall phenomenon, we are able to maintain that severe TMA requiring treatment is infrequent. Moreover, patients receiving either unrelated or mismatched grafts are particularly prone to severe TMA. Although not conclusive, our results confirm the impression that, whereas the prognosis of HUS appears generally favorable, current treatment for established transplant-related TTP cases is unsatisfactory. To improve results, careful monitoring of patients in the post-BMT period is recommended to identify the disease early; prompt, specific therapy may offer advantages over the more usual treatment of advanced cases.
